BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25185729)

  • 1. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.
    Musetti C; Quaglia M; Cena T; Chiocchetti A; Monti S; Clemente N; Magnani C; Dianzani U; Stratta P
    J Nephrol; 2015 Jun; 28(3):299-305. PubMed ID: 25185729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis.
    Sołtysiak J; Zachwieja J; Benedyk A; Lewandowska-Stachowiak M; Nowicki M; Ostalska-Nowicka D
    Minerva Pediatr; 2019 Feb; 71(1):4-11. PubMed ID: 27070416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
    Bock ME; Price HE; Gallon L; Langman CB
    Clin J Am Soc Nephrol; 2013 Aug; 8(8):1304-11. PubMed ID: 23620441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
    Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
    Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
    Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
    Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
    Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
    Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
    Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
    Wada T; Nangaku M; Maruyama S; Imai E; Shoji K; Kato S; Endo T; Muso E; Kamata K; Yokoyama H; Fujimoto K; Obata Y; Nishino T; Kato H; Uchida S; Sasatomi Y; Saito T; Matsuo S
    Kidney Int; 2014 Mar; 85(3):641-8. PubMed ID: 24429394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
    Segarra A; Jatem E; Quiles MT; Arbós MA; Ostos H; Valtierra N; Carnicer C; Salcedo MT
    Nefrologia; 2014; 34(1):53-61. PubMed ID: 24463863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
    Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
    Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Urokinase Receptor and Chronic Kidney Disease.
    Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
    N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
    Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
    Lv L; Wang F; Wu L; Wang JW; Cui Z; Hayek SS; Wei C; Reiser J; He K; Zhang L; Chen M; Zhao MH
    Nephrol Dial Transplant; 2020 Mar; 35(3):465-470. PubMed ID: 30124995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
    Franco Palacios CR; Lieske JC; Wadei HM; Rule AD; Fervenza FC; Voskoboev N; Garovic VD; Zand L; Stegall MD; Cosio FG; Amer H
    Transplantation; 2013 Aug; 96(4):394-9. PubMed ID: 23736353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J; Li YW; He Q
    Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
    Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
    Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.
    Fujimoto K; Imura J; Atsumi H; Matsui Y; Adachi H; Okuyama H; Yamaya H; Yokoyama H
    Clin Exp Nephrol; 2015 Oct; 19(5):804-14. PubMed ID: 25500737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
    Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.